G1 Therapeutics

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

G1 Therapeutics excels in Q4 with Cosela sales surge and optimistic 2023 outlook

G1 Therapeutics delivered strong financial results in Q4 2022, driven by the impressive performance of Cosela in the small cell lung cancer market. Despite organizational changes to conserve capital, the company remains focused on growth and innovation. With a solid cash balance projection for 2023 and a growing customer base, G1 Therapeutics is poised for continued success.

G1 Therapeutics reports robust Q1 performance and optimistic growth outlook

G1 Therapeutics demonstrated strong financial performance and commercial growth in Q1 2023, with COSELA showing promising results and a positive outlook for the future.
While facing challenges related to potential drug interactions, the company is well-positioned to capitalize on opportunities through upcoming data readouts and strategic decisions.
Investors can be optimistic about G1 Therapeutics' continued progress, supported by a solid financial foundation and a focus on maximizing COSELA's potential.

G1 Therapeutics reports resilient Q2 performance amidst challenges and opportunities

G1 Therapeutics delivered a strong financial performance in Q2 2023, showcasing resilience and strategic financial management amidst challenges.
The company's focus on advancing its clinical pipeline and securing survival results in early 2024 positions it for future growth and value creation.
While facing challenges such as a chemotherapy shortage and operational efficiency, G1 Therapeutics maintains stability and confidence in its financial outlook.
Opportunities lie in capitalizing on COSELA sales growth, advancing clinical programs, and leveraging financial flexibility for sustained growth and innovation.

G1 Therapeutics overcomes supply challenges, eyes growth in oncology

G1 Therapeutics exhibited resilience in revenue growth despite challenges with COSELA's market supply, showcasing operational strength.
The company's strong financial position and cost management efforts bode well for sustainable growth and value creation.
Exciting opportunities in clinical trials and market expansion present avenues for future success and competitive positioning in the oncology sector.

G1 Therapeutics excels in Q4 2023, poised for growth ahead

G1 Therapeutics demonstrated strong performance in Q4 2023 with notable revenue growth and expense management.
COSELA's market share and promising trial results highlight strengths in the product portfolio.
While challenges like trial result anticipation and cost efficiency persist, opportunities for growth and optimization are evident.
Overall, G1 Therapeutics shows promise with a healthy cash position and positive sales guidance for 2024.

G1 Therapeutics reports strong Q1 earnings and diversifies revenue streams

G1 Therapeutics delivered robust financial results, showcasing growth in revenue and cost management improvements in Q1 2024.
While facing challenges in managing expenses and advancing clinical trials, the company remains optimistic about revenue guidance and market opportunities.
With a solid cash position and strategic partnerships, G1 Therapeutics is well-positioned to drive future growth and innovation in the oncology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

G1 Therapeutics, Inc. is a commercial-stage oncology firm focused on the research and marketing of next-generation anticancer treatments.

- Transaction Will Maximize the Access and Uptake of COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - G1 Stockholders to Receive U.S. $7.15 Per Share in Cash - HOLBAEK, Denmark and RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Pharmacosmos A/S, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, and G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company focused on delivering next-generation therapies that improve the lives of those affected by cancer, today announced that Pharmacosmos A/S has successfully completed the previously announced tender offer to acquire all outstanding shares of G1 Therapeutics for U.S. $7.15 per share net to the holder in cash, without interest and less any applicable withholding taxes (the “Offer Price”), for a total equity value of approximately $405 million.

Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer

HOLBAEK, Denmark and RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharmacosmos A/S, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, and G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company focused on delivering next-generation therapies that improve the lives of those affected by cancer, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") relating to Pharmacosmos' previously announced acquisition of G1 Therapeutics. The expiration of the waiting period occurred at 11:59 p.m. EST on September 4, 2024.

Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period

NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating G1 Therapeutics, Inc. ( Nasdaq: GTHX ) , relating to its proposed merger with Kahn Swick & Foti, LLC (“KSF”). Under the terms of the proposal, KSF will commence a tender offer to purchase GTHX stock at a price of $7.15 per share.

GTHX SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Tender Offer of G1 Therapeutics, Inc.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of G1 Therapeutics, Inc. (NasdaqGS: GTHX) to Pharmacosmos A/S. Under the terms of the proposed transaction, shareholders of G1 will receive $7.15 in cash for each share of G1 that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the considera.

G1 THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of G1 Therapeutics, Inc. - GTHX

PetIQ

NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of Shareholders

G1 Therapeutics (GTHX) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to earnings of $0.14 per share a year ago.

G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates

- Entered into Definitive Merger Agreement to be Acquired by Pharmacosmos; Transaction Expected to Close in Late Third Quarter 2024 - - Achieved $15.8 Million in Net Revenue from Sales of COSELA® (trilaciclib) - - Drove Double Digit Quarter-Over-Quarter Growth in COSELA Vial Volume and Net Revenue - - Reaffirmed 2024 Net COSELA Revenue Guidance of Between $60 and $70 Million - - Due to the Pending Transaction with Pharmacosmos, G1 will Not Host a Conference Call and Webcast to Discuss the Second Quarter Financial Results and Business Update - RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update for the second quarter ended June 30, 2024.

G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights

MILWAUKEE , Aug. 7, 2024 /PRNewswire/ -- Ademi LLP is investigating GI (Nasdaq: GTHX) for possible breaches of fiduciary duty and other violations of law in its transaction with Pharmacosmos. Click here to learn how to join our investigation https://www.ademilaw.com/case/g1-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether G1 Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of G1 Therapeutics, Inc. (NASDAQ: GTHX) to Pharmacosmos A/S for $7.15 per share in cash is fair to G1 shareholders. Halper Sadeh encourages G1 shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether G1 and its board of di.

GTHX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of G1 Therapeutics, Inc. Is Fair to Shareholders

G1 Therapeutics (NASDAQ: GTHX ) stock is rocketing higher on Wednesday after the company announced an acquisition deal with Pharmacosmos Group. Pharmacosmos Group has agreed to acquire all outstanding shares of GTHX stock for $7.15 in cash.

Why Is G1 Therapeutics (GTHX) Stock Up 66% Today?

- Business Combination Expected to Provide Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Optimal Access to G1's COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - Pharmacosmos' Significant Resources and Expertise in Hematology and Supportive Care to Maximize Availability of COSELA for Patients with ES-SCLC - - Transaction Expands and Strengthens Pharmacosmos' Global Commercial Portfolio - - G1's Shareholders to Receive U.S. $7.15 per Share in Cash for a Total Equity Value of Approximately $405 Million - RESEARCH TRIANGLE PARK, N.C. and HOLBAEK, Denmark, Aug. 07, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company focused on delivering next-generation therapies that improve the lives of those affected by cancer, and Pharmacosmos A/S, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, today announced that they have entered into a definitive merger agreement under which Pharmacosmos A/S, through its U.S. subsidiary Pharmacosmos Therapeutics Inc., will acquire all outstanding shares of G1 Therapeutics common stock for U.S. $7.15 per share in cash for a total equity value of approximately $405 million, which represents a 68% premium to G1's closing share price on August 6, 2024 and a 133% premium to G1's prior 30-day volume weighted average price.

Pharmacosmos Group to Acquire G1 Therapeutics

RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 12,300 shares of G1's common stock and 6,150 restricted stock units (RSUs) to five hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”).

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the second quarter of 2024 on Thursday August 8, 2024, at 8:30 a.m.

G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

While small-capitalization biotechnology firms bring much potential to the table, they also represent a source of unpredictability. Nevertheless, for risk-takers, oncology specialist G1 Therapeutics (NASDAQ: GTHX ) appears quite enticing.

G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025

Biotechnology stocks can be thrilling and profitable when you're on the winning side of a trade. G1 Therapeutics' (NASDAQ: GTHX ) started hot, but then the bottom fell out after an unfortunate announcement.

Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble

RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as of the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets today, Monday, July 1, 2024.

G1 Therapeutics Added to the Russell 2000® and 3000® Indexes

G1 Therapeutics, Inc. faces a setback as a trial for triple-negative breast cancer fails to improve survival, leading to a significant market selloff. The company's main drug, trilaciclib, shows potential for reducing severe neutropenia but fails to meet the primary endpoint in the breast cancer trial. Despite financial challenges and market pessimism, G1 Therapeutics maintains an approved drug with growing sales and potential in niche markets like small cell lung cancer.

G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty

Shares of G1 Therapeutics Inc GTHX are trading lower after the company released topline results from the final OS analysis of its Phase 3 PRESERVE 2 trial evaluating the efficacy and safety of trilaciclib administered before chemotherapy (gemcitabine and carboplatin; GCb) for metastatic Metastatic Triple Negative Breast Cancer (TNBC).

Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday?

G1 Therapeutics (NASDAQ: GTHX ) stock is falling hard on Monday after the company provided investors with an update on its Phase 3 clinical trial of trilaciclib as a breast cancer treatment. G1 Therapeutics notes that this trial failed to meet its primary endpoint.

Why Is G1 Therapeutics (GTHX) Stock Down 56% Today?

G1 Therapeutics said on Monday its drug for a rare, aggressive form of breast cancer did not meet the main goal of overall survival in a late-stage trial.

G1 Therapeutics' breast cancer drug fails in late-stage trial

G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negativ

G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)

- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to Historical Data for the ADC Alone - - Exploratory Analysis of a More Comparable Patient Population Showed an Approximately Six-Month Improvement in Median OS Among Patients Receiving Trilaciclib in Combination with the ADC Compared to Historical ADC Data - - Prolonged OS Observed in Patients Receiving Trilaciclib with Prior Anti-PD-(L)1 Therapy and No Prior Oral CDK4/6 Inhibitor - - On-Target Effect of Trilaciclib Reduces Rates of Multiple Adverse Events Associated with the TROP2 ADC Including Myelosuppression and Diarrhea - - Results to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Meeting - RESEARCH TRIANGLE PARK, N.C., May 28, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the presentation of mature Phase 2 clinical trial results describing the positive impact of trilaciclib in combination with a TROP2 ADC (sacituzumab govitecan; SG) on overall survival (OS) and tolerability compared to SG alone based on historical data from the ASCENT trial1.

Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)

RESEARCH TRIANGLE PARK, N.C., May 23, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that mature Phase 2 results describing the positive impact of trilaciclib administered in combination with the TROP2 antibody-drug conjugate (ADC) sacituzumab govitecan (SG) on overall survival (OS) and tolerability compared to SG alone based on historical data from the ASCENT trial will be presented in a poster session during the upcoming 2024 American Society of Clinical Oncology (ASCO) Meeting.

G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting

RESEARCH TRIANGLE PARK, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Medical Officer Dr. Raj Malik and Chief Commercial Officer Andrew Perry will participate in a fireside chat at TD Cowen's 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA, on Wednesday, May 29, at 8:30AM EDT.

G1 Therapeutics to Participate in TD Cowen's 5th Annual Oncology Innovation Summit

RESEARCH TRIANGLE PARK, N.C. and SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, and Deimos Biosciences, a portfolio company of Jupiter Bioventures, announced a global licensing agreement (excluding the Asia-Pacific region) for lerociclib for radioprotective uses.

News for G1 Therapeutics Stock (GTHX)